Background: Depressed heart rate variability (HRV) reflects abnormal cardiac autonomic regulation and has been linked with increased cardiovascular risk and sudden cardiac death. High parathyroid hormone (PTH) levels have also been associated with an increased risk of sudden cardiac death in haemodialysis (HD) patients. Our aim was to investigate the association between HRV indices and PTH in HD patients. Methods: Continuous intradialytic electrocardiograms were repeated in stable HD patients 5 times every 2 weeks. The absolute values of high-frequency (HF) and low-frequency (LF) HRV components were calculated every 5 min and averaged during the first and last hour of each recording (distinguished by subscripts F and L, respectively). Pre-HD PTH, corrected calcium, and phosphate levels were measured before the first recording. Results: Data were analysed for 75 subjects aged 60 ± 15, 32% females, 37% diabetics. Baseline biochemical parameters were PTH 44 ± 32 pmol/l, calcium 2.3 ± 0.2 mmol/l, and phosphate 1.6 ± 0.4 mmol/l. All HRV indices showed intra-subject stability over the 5 recordings. Diabetics had lower LFL compared to non-diabetics (-5.5 ± 0.5 vs. -5.2 ± 0.5 after logarithmic transformation, p = 0.012). In non-diabetics, PTH correlated negatively with LFL and HFL (LFL r = -0.340, p = 0.020, HFL r = -0.325, p = 0.026) and phosphate correlated negatively with LFF (r = -0.427, p = 0.003), HFF (r = -0.442, p = 0.002) and HFL (r = -0.307, p = 0.040). Conclusion: High PTH and phosphate are associated with depressed HRV in non-diabetic dialysis patients. Prospective studies are needed to evaluate the role of mineral abnormalities in autonomic imbalance and arrhythmic risk in HD patients.

Keywords:
Heart rate variability, Haemodialysis, Parathyroid hormone
1.
Annual Data Report, US Renal Data System. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
2.
Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572-586.
3.
Sprague SM, Moe SM: The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol 2013;8:313-318.
4.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
5.
Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al: Serum iPTH, calcium and phosphate, and the risk of mortality in a European hemodialysis population. Nephrol Dial Transplant 2011;26:1948-1955.
6.
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
7.
Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, et al: Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010;31:1591-1598.
8.
Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, et al: Vitamin D, parathyroid hormone, and sudden cardiac death: results from the cardiovascular health study. Hypertension 2011;58:1021-1028.
9.
Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al: Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011;57:846-851.
10.
Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology: Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-1065.
11.
La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ; Autonomic Tone and Reflexes After Myocardial Infarction (ATRAMI) Investigators: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-484.
12.
Chandra P, Sands RL, Gillespie BW, Levin NW, Kotanko P, Kiser M, et al: Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrol Dial Transplant 2012;27:700-709.
13.
Zhang J, Yu X, Sun B, Bai J, Wei Y, Zha X, et al: Parathyroidectomy and heart rate variability in patients with stage 5 CKD. Clin J Am Soc Nephrol 2013;8:1378-1387.
14.
Polak G, Strozecki P, Grzesk G, Manitius J, Grabczewska Z, Przybyl R: Effect of parathormone on heart rate variability in hemodialysis patients. Auton Neurosci 2004;115:94-98.
15.
Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, et al: Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol 2011;22:1526-1533.
16.
CardioDay®, Holter ECG analysis software, user manual. Getemed Medizin- und Informationstechnik AG; 12/16/2006. Report No.: REF 90270-US 0505S1-LAB-Rev-C-GA-CardioDay-2-0-ENG_US.doc 12/16/2006.
17.
Ogino K, Burkhoff D, Bilezikian JP: The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 1995;136:3024-3030.
18.
Hara M, Liu YM, Zhen L, Cohen IS, Yu H, Danilo P Jr, et al: Positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are associated with increases in the current, If, and the slope of the pacemaker potential. Circulation 1997;96:3704-3709.
19.
Potthoff SA, Janus A, Hoch H, Frahnert M, Tossios P, Reber D, et al: PTH-receptors regulate norepinephrine release in human heart and kidney. Regul Pept 2011;171:35-42.
20.
Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al: Serum iPTH, calcium and phosphate, and the risk of mortality in a European hemodialysis population. Nephrol Dial Transplant 2011;26:1948-1955.
21.
Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol and Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-2633.
22.
Cunningham J, Locatelli F, Rodriguez M: Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-921.
23.
Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald LF, Stubbs JR, Wacker MJ: FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013;304:E863-E873.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.